Anavex Life Sciences Corp (AVXL)

[seventhwave]

Jefferies takeaways- new and emphasized communication:
Right off the bat Missling brought up PK/PD imminent and kept bringing it up another 1/2 dozen times esp. expecting it as actionable correlation that kicks off 3 trials this year.

Full genomic analysis of patients' genome are being fed into Ariana's data analysis tool to draw correl with systematic responders. This is now routine in oncology which AVXL is drawing on to reduce future trial risk (and full marks to AVXL for being thorough.)

Per a recent study, BDNF Val66Met polymorphism correlates with
higher frequency & severity of seizure. Also correlates with cognitive decline & increased AB accum in AD. A 2-73 normalizes BDNF expression in the hippocampus (this may have been brought up at the Angelman/Seizure presentation in FL a couple of weeks ago- missed it)

In other news, detailed Bryostatin study results and analysis from the Phase 2a and Expanded Access (EA) studies was just published in the Journal of Alzheimer's Disease: http://bit.ly/2sdl4JY
Saw their stock jump 12% today as it was apparently well received. Board input would be useful.